Brief: Nektar Says REZOLVE-AD Phase 2B Results For Rezpegaldesleukin Selected For Oral Presentation At EADV 2025
09/09/2025 12:18
Sept 9 (Reuters) - Nektar Therapeutics NKTR.O: NEKTAR ANNOUNCES REZOLVE-AD PHASE 2B RESULTS FOR REZPEGALDESLEUKIN SELECTED FOR LATE-BREAKER ORAL PRESENTATION AT EADV 2025 Source text: ID:nPn1WwZJVa Further company coverage: NKTR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nektar Therapeutics
See all newsBrief: Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment
U.S. STOCKS ON THE MOVEx-Microsoft, 3M, Twilio
U.S. STOCKS ON THE MOVEx-Microsoft, Nike, Nektar Therapeutics
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says